EUVIMEDEUVIMED entdecken
Open Access

Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy

Felix L Herr, Christian Dascalescu, Ricarda Ebner, Moritz L Schnitzer, Matthias P Fabritius, Christine Schmid-Tannwald, Mathias J Zacherl, Vera Wenter, Lena M Unterrainer, Matthias Brendel, Adrien Holzgreve, Rudolf A Werner und 8 weitere

Theranostics · 2025

DOI: 10.7150/thno.112588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2025. Verfasst von Felix L Herr und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Stomach Neoplasms, Intestinal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsStomach NeoplasmsIntestinal NeoplasmsBiomarkers, TumorOctreotideOrganometallic CompoundsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedProgression-Free SurvivalAdultPositron Emission Tomography Computed TomographyReceptors, SomatostatinRadiopharmaceuticalsKi-67 AntigenAged, 80 and overLutetium

Stichwörter der Autor:innen

GEP-NETKi-67Krenning scorePRRThistopathologyproliferation indexsomatostatin receptor

Substanzen

Biomarkers, TumorOctreotideOrganometallic CompoundsReceptors, SomatostatinRadiopharmaceuticalsKi-67 Antigenlutetium Lu 177 dotatateLutetium

Autor:innen und Institutionen

  • Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
  • Bayerisches Zentrum für Krebsforschung (BZKF), partner site Munich, Germany.
  • DZNE - German Center for Neurodegenerative Diseases, Munich, Germany.
  • Munich Cluster for Systems Neurology (SyNergy), University of Munich, Munich, Germany.
  • German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and LMU, Germany.

Zitieren

APA

Herr, F. L., Dascalescu, C., Ebner, R., Schnitzer, M. L., Fabritius, M. P., Schmid-Tannwald, C., Zacherl, M. J., Wenter, V., Unterrainer, L. M., Brendel, M., Holzgreve, A., Werner, R. A., Auernhammer, C. J., Spitzweg, C., Knösel, T., Burkard, T., Ricke, J., Heimer, M. M., Sheikh, G. T., & Cyran, C. C. (2025). Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. Theranostics. https://doi.org/10.7150/thno.112588

Vancouver

Herr FL, Dascalescu C, Ebner R, Schnitzer ML, Fabritius MP, Schmid-Tannwald C, et al. Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. Theranostics. 2025. doi:10.7150/thno.112588

BibTeX
@article{Herr2025,
  author = {Herr, Felix L and Dascalescu, Christian and Ebner, Ricarda and Schnitzer, Moritz L and Fabritius, Matthias P and Schmid-Tannwald, Christine and Zacherl, Mathias J and Wenter, Vera and Unterrainer, Lena M and Brendel, Matthias and Holzgreve, Adrien and Werner, Rudolf A and Auernhammer, Christoph J and Spitzweg, Christine and Knösel, Thomas and Burkard, Tanja and Ricke, Jens and Heimer, Maurice M and Sheikh, Gabriel T and Cyran, Clemens C},
  title = {Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy},
  journal = {Theranostics},
  year = {2025},
  doi = {10.7150/thno.112588}
}
Kostenlos starten →